Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Autor(es)

Kischkel, Brenda ^{[1, 2]} ; Rossi, Suelen A. ^{[1, 2]} ; Santos, Jr., Samuel R. ^{[1, 2]} ; Nosanchuk, Joshua D. ^{[3, 4]} ; Travassos, Luiz R. ^[5] ; Taborda, Carlos P. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Med Sch, Inst Trop Med Sao Paulo LIM53, Lab Med Mycol, Sao Paulo - Brazil

^[3] Albert Einstein Coll Med, Div Infect Dis Microbiol & Immunol, Dept Med, Bronx, NY 10467 - USA

^[4] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 - USA

^[5] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY; v. 10, SEP 3 2020.
• Citações Web of Science: 1

Resumo

Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused byCandidasp.,Cryptococcussp.,Paracoccidioidessp.,Histoplasmasp.,Coccidio idessp., andAspergillussp., in addition to providing important information on the use of different types of nanoparticles, nanocarriers and their corresponding mechanisms of action. (AU)

• Processo FAPESP: 18/26402-1 - Prospecção de novos epítopos com potencial vacinal no controle da infecção experimental por Histoplasma capsulatum
• Beneficiário: Brenda Kischkel
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 16/08730-6 - Patogenicidade fúngica: efeito do tabagismo, resposta imune e a modulação vacinal na paracoccidioidomicose e na histoplasmose
• Beneficiário: Carlos Pelleschi Taborda
• Modalidade de apoio: Auxílio à Pesquisa - Temático